Clinical and Financial Impact of eICU(R) Program Presented at American College of Chest Physicians.

Five Health Systems Share Their Experience

BALTIMORE -- VISICU, Inc. (NASDAQ:EICU) today announces that eight scientific abstracts demonstrating the clinical, financial, and organizational impact of its eICU([R]) Program are being presented at the American College of Chest Physicians' annual conference, "Experience CHEST 2006," currently in session in Salt Lake City. The abstracts are based on research performed by clinicians at Avera Health (Sioux Falls, SD), Memorial Hermann (Houston, TX), Parkview Health (Fort Wayne, IN), Saint Luke's Health System (Kansas City, MO) and University of Pennsylvania School of Medicine (Philadelphia, PA). The following are highlights of the findings and conclusions documented in these abstracts:

Financial benefits - The University of Pennsylvania documented a 29% increase in professional-fee billing for critical care as a result of more robust physician documentation associated with the use of eICU technology.

Improved ICU mortality rates and length of stay - Avera Health reported on the impact of eICU-ICU integration, demonstrating a 60% improvement in severity adjusted ICU mortality (observed ICU mortality versus predicted ICU mortality) and a 35% improvement in severity adjusted ICU length of stay (observed ICU length of stay versus predicted ICU length of stay) for ICUs with good integration as oppose to those without.

Increased use of best practices - Compliance with best practices has been shown to improve outcomes and reduce complications. However, many health systems struggle to implement these practices across their hospitals. Avera Health and Parkview Health each evaluated the impact of eICU clinicians supporting bedside caregivers with the implementation of ICU best practices. With added support from eICU clinicians, Parkview Health improved compliance with the IHI Ventilator bundle to over 95%, and Avera Health significantly improved blood glucose control. The IHI Ventilator bundle has been shown to reduce cases of ventilator-associated pneumonia and their associated cost, while glucose control has been shown to improve ICU mortality.

Improved effectiveness of rapid response teams - Rapid response teams have been shown to improve clinical outcomes for patients deteriorating on medical/surgical floors. However, unlike Commonwealth countries, rapid response teams in the United States often do not include a physician. Parkview Health evaluated the effect of their eICU intensivists participating "virtually" with their rapid response team. The result was a 32% reduction in non-ICU cardiac arrests and impressive nurse satisfaction.

Impact on Critical Care training - Memorial Hermann in conjunction with the University of Texas Medical School and Saint Luke's Health System each included Critical Care Fellows in their eICU care model. Each fellow was surveyed regarding his or her experience. All twelve fellows indicated that they believe the eICU Program saves lives and want to work in a hospital that uses the eICU Program, and ten of twelve fellows indicated that they believe that the eICU Program reduces malpractice exposure.

"The scientific evidence continues to emerge that this innovative care delivery model and patient care tools not only improve the quality of care delivered to our sickest patients in the intensive care unit, but can impact physician satisfaction and reimbursement and care to patients throughout the hospital," said Brian Rosenfeld M.D., Executive VP and Chief Medical Officer for VISICU.

All eight abstracts are published in a CHEST journal supplement. For information about accessing these abstracts or about the CHEST conference program contact the American College of CHEST Physicians.

APACHE III algorithms were used to define the predicted mortality risk for the Avera Health abstract. The APACHE III database is used to estimate the mortality risk for individual ICU patients using chronic health status information, severity of illness on ICU admission, age, prior length of stay and ICU admission diagnosis. APACHE is a registered trademark of Cerner Corporation.

About VISICU

VISICU, Inc. (NASDAQ:EICU) is a healthcare information technology and clinical solutions company focused on transforming the delivery of critical care through its eICU([R]) Program. The eICU Program restructures the practice of critical care by using remote monitoring technology to allow health systems to centralize scarce critical care trained staff to improve coverage and for earlier intervention to prevent or manage crises. A study (Crit Care Med 2004; 32:31-38) documented the clinical and financial benefits of the program. The eICU Program enables hospitals to meet The Leapfrog Group's ICU patient care safety standards. For more information, visit www.VISICU.com. VISICU([R]) and eICU([R])are registered trademarks of VISICU, Inc. All rights reserved. All other brand names, product names, company names, trademarks and service marks are the property of their respective owners.

Safe Harbor Statement

This release contains forward-looking statements that are made pursuant to the provisions of Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve a number of risks and uncertainties. Investors are cautioned that statements in this release that are not strictly historical statements constitute forward-looking statements. It is important to note that the company's performance, and actual results, financial condition or business could differ materially from those expressed in the forward-looking statements. The words "may", "could", "would", "should", "outlook", "positions us", "guidance", "expects", "estimates", "intends", "plans", "projects", "anticipates", "believes", "predicts", "potential" or the negative of these words, variations thereof or similar expressions are intended to identify such forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could materially affect actual results, levels of activity, performance or achievements. Factors that could cause results to differ materially from current expectations include, but are not limited to: market acceptance of our principal product offering and any new product releases; the price, performance and reliability of our products and services; our ability to attract and retain new customers and renewal rates of our existing customers; unanticipated delays or problems in releasing new products and services; financial and budget constraints of hospitals, changes in our pricing practices or our competitors' pricing practices and changes in the healthcare industry; the introduction or availability of competing products or services and other competitive factors; and changes in the government regulation of our products and services.